• DOI:10.1517/14740338.6.1.1
Corpus ID: 33505288

Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?

@article{Osman2007TamoxifeninducedNS,
  title={Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?},
  author={K. Osman and M. M. Osman and M. Ahmed},
  journal={Expert Opinion on Drug Safety},
  year={2007},
  volume={6},
  pages={1 - 4}
}

K. Osman, M. M. Osman, M. Ahmed

Published 2007

Medicine

Expert Opinion on Drug Safety

Tamoxifen is a cheap and effective estrogen-receptor antagonist, used as the adjuvant hormonal treatment of choice in women with estrogen-receptor-positive breast cancer. Tamoxifen-induced non-alcoholic steatohepatitis (NASH) may increase the demand on oncologists, not only with regard to screening for diabetes, but also for the suggested link of NASH with high incidence of coronary heart disease. At present, there is no guideline for treatment of hyperlipidaemia associated with tamoxifen… CONTINUE READING

View on Taylor & Francis

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed